{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:21:01Z","timestamp":1741324861280,"version":"3.38.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>To generate a novel oncolytic vaccinia virus with improved safety and productivity, the genome of smallpox vaccine strain LC16m8 was modified by a bacterial artificial chromosome system. By using LC16m8, a replicating virus homologous to the target virus, as a helper virus for the bacterial artificial chromosome system, we successfully recovered genome-edited infectious viruses. Oncolytic viruses with limited growth in normal cells were obtained by deleting the genes for vaccinia virus growth factor (VGF), extracellular signal-regulated kinase-activating protein (O1L), and ribonucleotide reductase (RNR) present in the viral genome. Furthermore, the amino acid residues of seven proteins involved in extracellular enveloped virus virion formation were replaced to the IHD-J strain sequence, which is known to highly express extracellular enveloped virus. In cultured cancer cells (HeLa), these modified viruses showed cytotoxicity and increased productivity, but it was confirmed that the cytotoxicity was suppressed in normal cells (normal human dermal fibroblasts). For <jats:italic>in vivo<\/jats:italic> safety evaluation, a modified virus (MD-RVV-\u0394RR-EEV6) in which the VGF, O1L, and RNR genes of LC16m8 were deleted and the genes of six extracellular enveloped virus-associated proteins were replaced with sequences derived from IHD-J strain, and another modified virus (MD-RVV) lacking only the VGF and O1L were administered intravenously to severe combined immunodeficiency mice. In the MD-RVV administration, animals in all dose groups died by 40 days after virus administration. On the other hand, after MD-RVV-\u0394RR-EEV6 administration, 3 out of 5 animals in the high and medium dose groups and all animals in the low dose group were still alive by day 71, the end of the observation period. These results demonstrate that genome editing of oncolytic vaccinia virus can delete genes involved in viral replication to improve safety in normal cells, while replacing genes involved in maturation improves proliferative potential in cancer cells.<\/jats:p>","DOI":"10.1371\/journal.pone.0312205","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:23:03Z","timestamp":1741285383000},"page":"e0312205","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel oncolytic vaccinia virus with multiple gene modifications involved in viral replication and maturation increases safety for intravenous administration while maintaining proliferative potential in cancer cells"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6500-7267","authenticated-orcid":true,"given":"Go","family":"Okita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-8591","authenticated-orcid":true,"given":"Kiyotaka","family":"Suenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"pone.0312205.ref001","first-page":"805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","author":"MS Ferguson","year":"2012","journal-title":"Adv Virol"},{"key":"pone.0312205.ref002","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/IJN.S116447","article-title":"Viruses as nanomedicine for cancer","volume":"11","author":"N Badrinath","year":"2016","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"pone.0312205.ref003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients","volume":"10","author":"A Samson","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"pone.0312205.ref004","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers","volume":"24","author":"S Downs-Canner","year":"2016","journal-title":"Mol Ther"},{"issue":"19","key":"pone.0312205.ref005","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"LK Mell","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"pone.0312205.ref006","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","article-title":"Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope","volume":"95","author":"A Vanderplasschen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0312205.ref007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02970145","article-title":"Viral mimicry of the complement system","volume":"28","author":"J Bernet","year":"2003","journal-title":"J Biosci"},{"issue":"Pt 9","key":"pone.0312205.ref008","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1099\/vir.0.030460-0","article-title":"The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins","volume":"92","author":"BC DeHaven","year":"2011","journal-title":"J Gen Virol"},{"issue":"2","key":"pone.0312205.ref009","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1006\/viro.1996.0142","article-title":"Extracellular enveloped vaccinia virus escapes neutralization","volume":"217","author":"Y Ichihashi","year":"1996","journal-title":"Virology"},{"issue":"1","key":"pone.0312205.ref010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/jvi.70.1.272-281.1996","article-title":"Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus","volume":"70","author":"AA McIntosh","year":"1996","journal-title":"J Virol"},{"issue":"2","key":"pone.0312205.ref011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41564-018-0288-2","article-title":"Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility","volume":"4","author":"C Beerli","year":"2019","journal-title":"Nat Microbiol"},{"issue":"4","key":"pone.0312205.ref012","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/JVI.06166-11","article-title":"The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1\/2 and promotes viral virulence","volume":"86","author":"M Schweneker","year":"2012","journal-title":"J Virol"},{"issue":"5","key":"pone.0312205.ref013","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/cells10050985","article-title":"Anti-tumor effects of MAPK-dependent tumor-selective oncolytic vaccinia virus armed with CD\/UPRT against pancreatic ductal adenocarcinoma in mice","volume":"10","author":"H Kurosaki","year":"2021","journal-title":"Cells"},{"issue":"7","key":"pone.0312205.ref014","doi-asserted-by":"crossref","first-page":"e1000984","DOI":"10.1371\/journal.ppat.1000984","article-title":"Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis","volume":"6","author":"DB Gammon","year":"2010","journal-title":"PLoS Pathog"},{"issue":"5","key":"pone.0312205.ref015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.15252\/emmm.201607296","article-title":"Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models","volume":"9","author":"KG Potts","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"7","key":"pone.0312205.ref016","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"SJ Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"19","key":"pone.0312205.ref017","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1073\/pnas.192420599","article-title":"Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells","volume":"99","author":"A Domi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0312205.ref018","doi-asserted-by":"crossref","first-page":"534, 536, 538","DOI":"10.2144\/01313st07","article-title":"Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper","volume":"31","author":"TM Timiryasova","year":"2001","journal-title":"Biotechniques"},{"issue":"18","key":"pone.0312205.ref019","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection","volume":"79","author":"S Morikawa","year":"2005","journal-title":"J Virol"},{"key":"pone.0312205.ref020","author":"T Murakami","year":"2021"},{"key":"pone.0312205.ref021","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-60761-652-8_30","article-title":"En passant mutagenesis: a two step markerless red recombination system","volume":"634","author":"BK Tischer","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"3","key":"pone.0312205.ref022","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/JVI.02797-14","article-title":"Evolution of and evolutionary relationships between extant vaccinia virus strains","volume":"89","author":"L Qin","year":"2015","journal-title":"J Virol"},{"issue":"16","key":"pone.0312205.ref023","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Y Aye","year":"2015","journal-title":"Oncogene"},{"issue":"16","key":"pone.0312205.ref024","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1016\/S0021-9258(17)39337-7","article-title":"Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits","volume":"260","author":"Y Engstr\u00f6m","year":"1985","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0312205.ref025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1349-7006.2006.00244.x","article-title":"ERK MAP kinase in G cell cycle progression and cancer","volume":"97","author":"S Torii","year":"2006","journal-title":"Cancer Sci"},{"issue":"1","key":"pone.0312205.ref026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"J Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"pone.0312205.ref027","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cells9010198","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"U Degirmenci","year":"2020","journal-title":"Cells"},{"key":"pone.0312205.ref028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"L Li","year":"2020","journal-title":"Front Oncol"},{"key":"pone.0312205.ref029","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"GL Smith","year":"2002","journal-title":"J Gen Virol"},{"issue":"2","key":"pone.0312205.ref030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"CS Shemesh","year":"2021","journal-title":"Mol Ther"},{"key":"pone.0312205.ref031","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1348-0421.2003.tb03393.x","article-title":"Autologous cancer vaccine: a novel formulation","volume":"47","author":"T Ohno","year":"2003","journal-title":"Microbiol Immunol"},{"issue":"6","key":"pone.0312205.ref032","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/vox.12935","article-title":"A novel cancer immunotherapy utilizing autologous tumour tissue","volume":"115","author":"H Park","year":"2020","journal-title":"Vox Sang"},{"key":"pone.0312205.ref033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","article-title":"Armed oncolytic viruses: a kick-start for anti-tumor immunity","volume":"41","author":"JF de Graaf","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"pone.0312205.ref034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"ZS Guo","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:23:22Z","timestamp":1741285402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312205"}},"subtitle":[],"editor":[{"given":"Brian M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0312205","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}